Emerging approaches in preventing cardiovascular disease

British Medical Journal

Volumn 318, Issue 7194, 1999, Pages 1337-1341

  Loan, Eva M ^a   Yusuf, Salim ^a  

^a HAMILTON HEALTH SCIENCES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; BETA CAROTENE; CYANOCOBALAMIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOLIC ACID; HOMOCYSTEINE; PYRIDOXINE; RAMIPRIL; RETINOL; TRANDOLAPRIL;

AMINO ACID BLOOD LEVEL; ATHEROSCLEROSIS; BLOOD CLOTTING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; HUMAN; HYPERHOMOCYSTEINEMIA; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; STROKE; EVIDENCE BASED MEDICINE; OXIDATIVE STRESS; PHYSIOLOGY; RISK ASSESSMENT;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIOXIDANTS; CARDIOVASCULAR DISEASES; EVIDENCE-BASED MEDICINE; HOMOCYSTEINE; HUMANS; OXIDATIVE STRESS; RISK ASSESSMENT; RISK FACTORS; VITAMIN E;

EID: 0033561953     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. 1 Goldman L, Cook EF. The decline in ischemic heart disease mortality rates. An analysis of the comparative eiffects of medical interventions and changes in lifestyle. Am Intern Med 1984;101:825-36.
2. 2 Cordon T, Garcia-Palmiere MR, Kagan A, Kannel WB, Schiffman J. Differences in coronary heart disease in Framingham, Honolulu and Pueto Rico. J Chrom Dis 1974;27:329-44.
3. 3 Verschuren WMM, Jatobs DR, Bloemberg BPM, Kromhouml D, Menotti A, Aravanis C. et al. Serum total tholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study. JAMA 1995;274:131-6.
4. 4 Kannel WB, Castelli WP, Gordon T. Cholesterol in the prdiction of atherosclerotic disease. New perspectives based on the Framinghani Study. Ann Intem Med 1979;90:85-91.
5. 5 Steinberg D. Antioxidants in the prevention of human atherosclerosis. Summary of the proceedings of a National Heart Lung and Blood Institute workshop: Septenber 5-6, 1991, Bethesda, Maryland. Circulation 1992;85:2338-43.
6. 6 Berliner JA, Navab M, Fogelman AM, Frank JS, Demer LL, Edwards PA, et al. Atherosclerosis: basic mechanisms. Oxidation, inflammation and genetics. Circulation 1995;91:2488-96.
7. 7 Rinum EB, Ascherio A, Giovannucci E, Spiegelman D, Stampler MJ, Willett WC. Vegetable, fruit and cereal fiber intake and risk of coronary heart disease among men. JAMA. 1996;275:147-51.
8. 8 Jha P, Flather M, Lonn E, Farkouh M, Yusuf S. The antioxidant vitamins (F.C and beta-carotene) and cardiovascular disease: a critical summary of epidermiological and clinical trial data. Ann Intern Med 1995;123:860-72.
9. 9 Lonn EM, Yusuf S. Is there a role for antioxidant vitamins in the prevelion of cardiovascular diseases? An update on epidemiological and clinical trials data. Can J Cardiol 1997;13:957-65.
10. 10 Stampler MJ, Hennekens CH, Manson JE. Colditz GA, Rosner B, Willett WC. Vitamin F consumption and the risk of coronary disease in women. N Engl J Med 1993;328:1444-9.
11. 11 Kushi LH, Fulsom AR. Prineas RJ, Mink PJ, Wu Y, Bostick RM, Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women. N Engl J Med 1996; 334:1156-62.
12. 12 Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willett WC. Vitamin E consumption and the risk of cotonary heart disease in men. N Engl J Med 1993;328:1450-6.
13. 13 Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin F. and beta carotene on the incidence of lung cancer and other cancers in male smokers, N Engl J Med 1991;330:1029-35.
14. 14 Rapola JM, Virtamo, J. Haukka JK, Heinonen OP, Albanes D. Taylor PR, et al. Effect of vitamin F. and beta carotene on the incidence of angina pectoris: a randomized, double-blind, controlled trial. JAMA 1996;275: 693-8.
15. 15 Rapola JM, Virtamo J, Ripatti S, Huttunen JK, Albanes D, Taylor PR, et al. Randomised trial of α-tocopherol and β-carotene supplements on incidence of major coronary events in men with previous myocardial infarction, Lancet 1997;349:1715-20.
16. 16 Blot WJ, Li JY, Taylor PR. Guo W, Dawsey S, Wang GQ, et al. Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst 1993; 85: 1483-92.
17. 17 Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ, et al. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge heart antioxidant study (CHAOS). Lancet 1996;347:781-6.
18. 18 Omenn GS, Goodman GE, Thornquist MD, Balmes. J, Gullen MR, Glass A, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996;334:1150-5.
19. 19 Hennekens CH, Buring JE, Manson JE, Stampfer M, Rosner B, Cook NR, et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease, N Engl J Med 1996;334:1145-9.
20. 19a Greenberg ER, Bacon JA, Karagas MR, Stukel TA, Nierenberg DW, Stevens MM, et al. Mortality associated with low plasma concentration of beta carotene and the effect of oral supplementation, JAMA 1996; 275:699-703.
21. 20 Wilson TS, Datta SB, Murrell JS, Andrews CT. Relation of vitamin C levels to mortality in a geriatric hospital: a study of the effect of vitamin C administration. Age Aging 1973;2:163-71.
22. 21 Walldius G, Erikson U, Olsson AG, Bergstrand L, Hadell K, Johansson J, et al. the effect of probucol on femoral atherosclerosis: the probucol quantitative regression Swedish trial (PQRST). Am J Cardiol 1994;74: 875-83.
23. 22 Rodes, J, Cole G, Lesperance J, Bourassa MG, Doucet S, Bilodean L, et al. Prevention of restenosis after angioplasty in small coronary arteries with probucol, Circulation 1098;97:129-36.
24. 23 Lonn F.M, Yusuf S, Prabhat J. Montague TJ, Teo KK, Benedict CR, et al. Emerging role of anglorensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 1994;90:2056-69.
25. 24 Mancini GBJ. Henry GC, Macaya C, O'Neill BJ, Pucillo AL, Carere RG, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) study. Circulation 1996;94:258-65.
26. 25 Wright RA, Flapati AD,Alberti KG, Ludlam CA, Fox KAA, et al. Effect of caplopril therapy on endogenous fibrinolysis in men with recent uncomplicated myocardial infarction. J Am Coll Cardiol 1994;24:67-73.
27. 26 Cambieu F, Poirier O, Lecerf L, Evans A, Cambou J-P, Arveller D, et al. Deletion polymorphism in angiotensin-converting enzyme gene associated with parental history of myocardial infarction. Nature 1992; 359:641-4.
28. 27 Alderman MH, Madbavan SH, Ooi WL, Cohen H, Sealey JE, Laragh JH, et al. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 1991;324:1098-104.
29. 28 Meade TW Cooper JA, Pearl WS. Plasma renin activity and ischemic heart disease. N Engl J Med 1993;329:616-9.
30. 29 Samani NJ, Thompson JR, O'Toole L, Channer K, Woods KL. A meta-analysis of the associations of the deletion allele of the angiotensin-converting enzyme gene with myocardial infarction. Circulation. 1996;94:708-12.
31. 30 Acute Infarction Ramipril Efficacy (AIRF.) Study Investigators, Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of bean failure, Lancet 1993;342:821-8.
32. 31 Kober L, Torp-Peterson C., Carlsen JE, Bagger H, Eliasen P, Lynghorg K, et al for the Trandolapril Cardiac Evaluation (TRACE) Study Group. A clinical trial of the angiotensin-converting enzyme inhibitor tradolapril in patients with left ventricular dysfunction after myocardial infarctionion. N Engl J Med 1995;833:1670-6.
33. 32 Rutherford JD, Pfeffer MA, Moye LA, Davis BR, Flaker G.C. Kowey PR, et al on behalf of the SAVE investigators. Effects of captopril on ischemic events after myocardial infarction. Results of the survival and ventricular enlargement trial. Circulation 1994;90:1731-8.
34. 33 Yusuf S. Pepine CJ, Garces C, Pouleur H, Salem D, Kostis J, et al. Effect enalapril on myocarial infarction and unstable angina in patients with low ejection fractions. Lancet 1992;340:1173-8.
35. 34 Yusuf S, Lonn EM. Anti-ischemic effects of ACE,-inhibitors; Review of current clinical evidence and ongoing clinical trials. Eur Heart J 1998;19(suppl J):J36-44.
36. 35 McCully KS, Wilson RB. Homocysteine. theory of arteriosclerosis. Atherosclerosis 1975;22:215-27.
37. 36 Mayer EL, Jacobson DW, Robinson K. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol 1996;27:517-27.
38. 37 Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995;274: 1049-57.
39. 38 Graham IM, Daly LE, Refsum HM, Robinson K, Brattstrom LE, Ueland PM, et al. Plasma homocysteine as a risk factor for vascular disease. JAMA 1997;277:1775-81.
40. 39 Nygard O, Nordrehaug JE, Refsum HM, Ueland PM, Farstad M, Vollset SF. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997;337:230-6.
41. o from diet and supplements in relation to risk of coronary heart disease in women. JAMA 1998;279:359-64.
42. o concentrations. Risk factors for stroke, peripheral vascular disease and coronary arrery disease. Circulation 1998;97:437-43.
43. 42 Danesh J, Lewington S. Plasma homocysteine and coronary heart disease: systematic review of published epidemiological studies. J Cardiovasc Risk 1998;5:229-32.